The deregulation of oncoproteins such as Myc and Bcl-2 and tumor suppressors such as p53 might also contribute to RP abnormalities during tumor evolution with the relative importance of these factors being further dictated by both tissue and tumor heterogeneity [27, 44]. The gene discussed is BCL2; the disease is neoplasm.